Spruce Street Capital LP Acquires New Shares in LB Pharmaceuticals Inc $LBRX

Posted by Geri Gentry on Jun 16th, 2026

Spruce Street Capital LP acquired a new stake in LB Pharmaceuticals Inc (NASDAQ:LBRX – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 1,005,593 shares of the company’s stock, valued at approximately $22,384,000. LB Pharmaceuticals makes up approximately 7.4% of Spruce Street Capital LP’s holdings, making the stock its 3rd largest position. Spruce Street Capital LP owned about 3.97% of LB Pharmaceuticals as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Jane Street Group LLC increased its position in shares of LB Pharmaceuticals by 4.6% in the 4th quarter. Jane Street Group LLC now owns 31,733 shares of the company’s stock valued at $706,000 after buying an additional 1,388 shares in the last quarter. Bank of America Corp DE acquired a new position in LB Pharmaceuticals in the 3rd quarter worth $27,000. Strs Ohio acquired a new position in LB Pharmaceuticals in the 4th quarter worth $76,000. Police & Firemen s Retirement System of New Jersey acquired a new position in LB Pharmaceuticals in the 4th quarter worth $98,000. Finally, SG Americas Securities LLC acquired a new position in LB Pharmaceuticals in the 4th quarter worth $143,000.

LB Pharmaceuticals Price Performance

LB Pharmaceuticals stock opened at $28.50 on Tuesday. The firm has a 50-day moving average of $29.09 and a 200-day moving average of $24.66. LB Pharmaceuticals Inc has a one year low of $13.36 and a one year high of $33.47. The company has a market cap of $817.38 million and a price-to-earnings ratio of -16.47.

LB Pharmaceuticals (NASDAQ:LBRX – Get Free Report) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.67) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.08. As a group, sell-side analysts expect that LB Pharmaceuticals Inc will post -3.58 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Craig Hallum assumed coverage on shares of LB Pharmaceuticals in a research note on Friday, April 10th. They issued a “buy” rating and a $36.00 target price for the company. Weiss Ratings raised shares of LB Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday. HC Wainwright reaffirmed a “buy” rating on shares of LB Pharmaceuticals in a research note on Tuesday, May 26th. Stifel Nicolaus upped their target price on shares of LB Pharmaceuticals from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Friday, March 27th. Finally, Roth Mkm reaffirmed a “buy” rating and issued a $37.00 target price on shares of LB Pharmaceuticals in a research note on Sunday, May 17th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.40.

Check Out Our Latest Analysis on LBRX

LB Pharmaceuticals Profile

(Free Report)

We are a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, which we believe has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries, not including the United States, because the development and regulatory requirements of the U.S.